The money will be used to advance the Syntax platform, DNA Script's first commercial product that is powered by its proprietary enzymatic DNA synthesis technology, the company said. According to DNA Script, Syntax can help scientists rapidly print synthetic nucleic acids for genomics and molecular biology applications. On-demand printing enables labs to iterate without waiting days or weeks to receive genetic material from third-party service providers.

DNA Script is a life sciences technology company developing novel and efficient ways to design and manufacture nucleic acids.

Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the funding round, along with Healthcor Management, Eurekare, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management and Research Company, Columbia Threadneedle Investments, Casdin Capital plus other investors that participated in the first financing round.

DNA Script adds $165M to coffers
DNA Script has raised $165 million in a series C financing round led by Coatue Management and Catalio Capital Management.

DNA Script joins Genome Project-write's advisory board
DNA Script has joined the industrial advisory board of Genome Project-write, which has developed a computer-aided design tool for genome design.

DNA Script launches benchtop DNA printer
DNA Script has launched Syntax, a benchtop DNA printer designed for molecular biology and genomics applications. The printer is designed to enable onsite...